Cynata Therapeutics Limited (ASX:CYP)

Australia flag Australia · Delayed Price · Currency is AUD
0.322
+0.002 (0.63%)
Apr 29, 2026, 3:41 PM AEST
65.13%
Market Cap 75.99M
Revenue (ttm) 1.69M
Net Income (ttm) -8.40M
Shares Out 237.45M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,171
Average Volume 163,312
Open 0.320
Previous Close 0.320
Day's Range 0.310 - 0.330
52-Week Range 0.145 - 0.435
Beta 1.08
RSI 48.01
Earnings Date May 27, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a n... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 2
Stock Exchange Australian Securities Exchange
Ticker Symbol CYP
Full Company Profile

Financial Performance

In fiscal year 2025, Cynata Therapeutics's revenue was 1.89 million, a decrease of -18.59% compared to the previous year's 2.32 million. Losses were -9.39 million, -3.63% less than in 2024.

Financial Statements

News

There is no news available yet.